PaxMedica describes itself as a “clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders.”
While it’s still early in the day, PXMD stock is off to an excellent start. As of this writing, it is up more than 40%. This could be the next hot IPO that investors have been searching for. The question remains: Just how high can it go?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
good 👍